Medtronic Updates Interim CFO Compensation
Ticker: MDT · Form: 8-K/A · Filed: Aug 16, 2024 · CIK: 1613103
| Field | Detail |
|---|---|
| Company | Medtronic PLC (MDT) |
| Form Type | 8-K/A |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $12,500, $500,000, $1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, amendment, cfo
Related Tickers: MDT
TL;DR
Medtronic amended its filing to detail new pay for its interim CFO.
AI Summary
Medtronic plc filed an 8-K/A on August 16, 2024, to update a prior disclosure regarding compensation arrangements for its interim Chief Financial Officer (CFO). This amendment follows the Compensation Committee's approval of new compensation terms for the interim CFO, effective June 21, 2024.
Why It Matters
This filing clarifies the compensation structure for Medtronic's interim CFO, providing transparency on executive pay arrangements. Investors can review these details to understand executive compensation policies.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous disclosure regarding executive compensation, which typically carries low risk unless it reveals significant unexpected changes.
Key Players & Entities
- Medtronic plc (company) — Filer of the 8-K/A
- Interim Chief Financial Officer (person) — Subject of the compensation arrangement update
- Compensation Committee (company) — Approved the new compensation arrangements
- June 21, 2024 (date) — Effective date of the compensation arrangements
- August 16, 2024 (date) — Filing date of the 8-K/A
FAQ
What is the purpose of this 8-K/A filing?
The purpose of this 8-K/A filing is to update a prior disclosure regarding new compensation arrangements approved by the Compensation Committee for Medtronic's interim Chief Financial Officer.
When were the new compensation arrangements for the interim CFO approved?
The new compensation arrangements for the interim CFO were approved by the Compensation Committee.
What is the effective date of these compensation arrangements?
The compensation arrangements are effective as of June 21, 2024.
Who is the subject of the compensation update?
The subject of the compensation update is Medtronic's interim Chief Financial Officer.
What type of filing is this, and when was it filed?
This is an 8-K/A filing, which was filed on August 16, 2024.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 9.6 · Accepted 2024-08-16 07:01:42
Key Financial Figures
- $0.0001 — registered Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange
- $12,500 — biweekly cash stipend in the amount of $12,500, effective as of August 3, 2024 and (ii
- $500,000 — ined Mr. Corona's annual base salary of $500,000, target bonus equal to 70% of annual ba
- $1 million — alary, and long-term incentive grant of $1 million granted on July 29, 2024. SIGNATURES
Filing Documents
- mdt-20240621.htm (8-K/A) — 60KB
- 0001613103-24-000133.txt ( ) — 366KB
- mdt-20240621.xsd (EX-101.SCH) — 7KB
- mdt-20240621_def.xml (EX-101.DEF) — 27KB
- mdt-20240621_lab.xml (EX-101.LAB) — 54KB
- mdt-20240621_pre.xml (EX-101.PRE) — 29KB
- mdt-20240621_htm.xml (XML) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Medtronic plc By /s/ Ivan K. Fong Date: August 16, 2024 Ivan K. Fong Executive Vice President, General Counsel and Secretary